New gel injection aims to smooth neck wrinkles
NCT ID NCT05741034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested JUVÉDERM® VOLITE™, a gel made from hyaluronic acid and lidocaine, to safely and effectively reduce neck lines in Chinese adults. About 159 participants with moderate to severe neck lines were randomly assigned to receive the injection or no treatment. The main goals were to see if the gel improved neck lines by at least one grade and to monitor any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JUVÉDERM® VOLITE™ (hyaluronic acid gel with lidocaine)
- What this could lead to
- If it works, this could offer a minimally invasive option to reduce neck lines and improve skin quality.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet published. The treatment is cosmetic, not life-changing, and may cause side effects like swelling or bruising.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
159 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Dec 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants in general good health as determined by Treating Investigator's (TI) judgment, including no known active pandemic infection. * Participants seeking improvement of transverse neck lines and hydration in neck area. * Has moderate or severe transverse neck lines (ATNLS Grade 2 or 3) on EI live assessment. * The participant is able to achieve at least a 1-point improvement in Allergan Transverse Neck Lines Scale (ATNLS) score with the allowed injection volume in the judgment of TI. Exclusion Criteria: * Neck deformity or significant skin laxity with severe redundant folds. * History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA (hyaluronic acid) products, or Streptococcal protein, or is planning to undergo desensitization therapy during the study. * Have a history of or currently suffer from autoimmune disease (e.g., rheumatoid arthritis, Crohn's disease). * Current cutaneous inflammatory or infectious processes (e.g., acne, herpes, dermatitis), abscess, an unhealed wound, or a cancerous or precancerous lesion on skin of the neck. * History of thyroid cancer, thyroid-related diseases, skin cancer of the neck, radiation of the treatment area, or de novo cancer in the treatment area. * Tendency to develop hypertrophic scarring. * Has ever received permanent soft tissue fillers (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene), calcium hydroxyapatite filler, or autologous fat in the neck area. * Has undergone neck surgery. * Semi-permanent soft tissue fillers (e.g., poly-L-lactic acid, polycaprolactone) in the neck area within 2 years before enrollment. * Botulinum toxin in the neck area within 6 months before enrollment. * Neck tattoos, piercings, pigmentation, hair, or past trauma that would interfere with the visualization of the neck area for the effectiveness assessments.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neck lines are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital /ID# 243982
Beijing, Beijing Municipality, 100730, China
-
China-Japan Friendship Hospital /ID# 243984
Beijing, Beijing Municipality, 100029, China
-
Huashan Hospital, Fudan University /ID# 244044
Shanghai, Shanghai Municipality, 200040, China
-
Peking University First Hospital /ID# 243980
Xicheng District, Beijing Municipality, 100034, China
-
The Third Affiliated Hospital, Sun Yat-Sen University /ID# 243987
Guangzhou, Guangdong, 510630, China
-
Tianjin Medical University General Hospital /ID# 244107
Tianjin, Tianjin Municipality, 300052, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 243981
Wuhan, Hubei, 430022, China
-
Wuxi People's Hospital /ID# 245875
Wuxi, Jiangsu, 214023, China
-
Zhongda Hospital Southeast University /ID# 243986
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.